Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health
Genexis Health
Independent evidence summaries

What the research actually shows.

Evidence summaries for peptides and related compounds — what the studies found, what they did not, and how strong the evidence actually is. We sell nothing, so no page here has a reason to overstate a finding.

Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply anything.
Compounds covered
0
Evidence grades
0
Products sold
0
Compound index

Start with the evidence

Each page sets out what the research found, what it did not, the reported risks, and the regulatory position — with the primary literature linked throughout.

Metabolic Ozempic

Semaglutide

Approved

A long-acting analogue of GLP-1, a hormone the gut releases after eating. Structural changes — an Aib substitution that resists enzymatic breakdown, and a fatty acid chain that binds albumin — extend its half-life from minutes to about a week.

Read the evidence
Metabolic Mounjaro

Tirzepatide

Approved

A single molecule that activates two incretin receptors — GIP and GLP-1 — built on a GIP backbone with substitutions that resist degradation and a fatty acid chain for weekly dosing.

Read the evidence
Metabolic

Retatrutide

Phase 3

An investigational agonist at three receptors — GIP, GLP-1 and glucagon. The glucagon component is what distinguishes it, and is intended to raise energy expenditure alongside the appetite suppression the other two provide.

Read the evidence
Melanocortin

Melanotan II

Phase 1

A synthetic cyclic analogue of alpha-MSH developed at the University of Arizona in the 1980s. Unlike its relative Melanotan I it is non-selective, activating melanocortin receptors across subtypes, which is the source of both its effects and its problems.

Read the evidence
Dermal

GHK-Cu

Phase 2

A naturally occurring tripeptide that binds copper, first isolated from human plasma in the 1970s. Plasma levels decline with age, which is the observation most claims about it are built on. It is a cosmetic ingredient, not a medicine.

Read the evidence
Repair

BPC-157

Animal only

A synthetic peptide corresponding to a partial sequence of a protein found in human gastric juice. It is among the most discussed compounds in this space and among the least supported by human evidence.

Read the evidence
How we grade

Seven levels, plainly labelled

The grade reflects the best available human evidence. It is not a recommendation, and a high grade does not mean a compound is appropriate for anyone in particular.

Approved

Licensed by at least one major regulator for a specific indication, on the strength of completed phase 3 trials. Approval is for that indication in that population — it is not a general endorsement of the compound.

Phase 3

Large randomised trials in humans are complete or under way, but the compound is not licensed. Efficacy and common adverse effects are reasonably well characterised; long-term safety may not be.

Phase 2

Tested in humans for efficacy at a modest scale. Enough to show a signal and characterise short-term tolerability, not enough to establish safety or durability. Most compounds that reach this stage still fail.

Phase 1

Studied in small numbers of humans, usually for safety and pharmacokinetics rather than whether it works. A phase 1 result says almost nothing about effectiveness.

Animal only

Evidence comes from rodents or other animal models, with no published controlled human trials. Most compounds that look promising in animals do not replicate in people — the attrition rate from animal model to approved drug is well over 90%.

In vitro

Evidence comes from cell culture or biochemical assays. This can establish that a compound does something to cells in a dish. It establishes nothing about what it does in a living body.

Failed trials

Taken into human trials and did not outperform placebo on its primary endpoint, or development was discontinued. This is stronger evidence than "untested" — it is evidence of absence, not absence of evidence.

Editorial standards

How these pages are written

01

Limitations get equal billing

Every compound page has a section headed "what the evidence does not show", and it is as prominent as the findings. A summary that only lists positive results is marketing, whatever it calls itself.

02

Evidence is graded, not implied

Each compound carries a grade from "approved medicine" down to "laboratory studies only". Volume of literature does not raise the grade — a thousand mouse papers is still animal evidence.

03

Negative results are reported

Compounds that went into human trials and failed are listed as failed. That is more useful than silence, and it is information sellers have no reason to give you.

04

No dosing, ever

We describe what studies found, not how to use anything. No doses, no routes, no protocols — not on request either. That is the line between an information resource and something else.

Where we stand

We don't sell anything

Genexis Health Ltd. holds no stock, takes no orders and arranges no supply. There is no price list on this site and no enquiry that leads to a sale. That is deliberate — an information resource with something to sell is an advertisement, and it should be read as one.

Several compounds described here are prescription-only medicines. Several more are investigational products no regulator has approved. If you are considering any of them, the conversation to have is with a doctor, not with a supplier.

  • No products, no prices, no stock
  • No dosing or administration guidance
  • Limitations published alongside findings
  • Primary literature linked throughout
  • Corrections welcomed and acted on
Community

Discussion, harm reduction and questions

Our Telegram and Instagram are where the discussion happens — safer practice, reading the literature, and questions about what the evidence does and doesn't support. No selling, and no dosing advice there either.

Join the discussion@genexishealth

Information only. Everything on this site is a summary of published research, provided for general information. It is not medical advice, not a treatment recommendation, and not a substitute for consultation with a qualified healthcare professional. Genexis Health does not sell, supply or arrange the supply of any compound described here. Many of the compounds covered are prescription-only medicines, investigational products that no regulator has approved, or substances regulators have issued public warnings about. Nothing here should be read as suggesting any of them is safe or appropriate for you to use.